Abi-Ayad N, Kodjikian L, Couturier J
Service d'ophtalmologie, hôpital de la Croix-Rousse, 103, grande rue de la Croix-Rousse, 69317 Lyon cedex 04, France.
J Fr Ophtalmol. 2011 Apr;34(4):259-64. doi: 10.1016/j.jfo.2010.11.012.
Genome study and expression profiling of the tumor seem to be the most significant biologic prognostic factor in uveal melanoma. Many cytogenetic and molecular tests are reported; our aim was to assess their ability to detect high metastatic risk patients through a literature review. Standard karyotyping, fluorescence in situ hybridization and microsatellite analysis are not adequate. DNA-based genome techniques must analyse the entire genome (comparative genomic hybridization [CGH]) and, optimally, detect chromosome 3 isodisomy ("single-nucleotid polymorphism" SNP-array). Multiplex ligation-dependent probe amplification (MLPA) is less expensive than array-CGH, but its interpretation may be delicate. Gene expression profiling is the most accurate molecular test for predicting metastatic death in patient with uveal melanoma even if it remains a costly technique. These prognostic tests could be useful to identify high-risk patients in future adjuvant therapy protocols.
肿瘤的基因组研究和表达谱分析似乎是葡萄膜黑色素瘤最重要的生物学预后因素。已有许多细胞遗传学和分子检测方法的报道；我们的目的是通过文献综述评估它们检测高转移风险患者的能力。标准核型分析、荧光原位杂交和微卫星分析并不充分。基于DNA的基因组技术必须分析整个基因组（比较基因组杂交[CGH]），并且最好能检测到3号染色体等臂双体（“单核苷酸多态性”SNP阵列）。多重连接依赖探针扩增（MLPA）比阵列CGH成本更低，但其解读可能较为复杂。基因表达谱分析是预测葡萄膜黑色素瘤患者转移死亡最准确的分子检测方法，尽管它仍然是一项成本高昂的技术。这些预后检测方法可能有助于在未来的辅助治疗方案中识别高危患者。
